Skip to main content
. 2014 Aug 7;4(4):339–348. doi: 10.1093/jpids/piu081

Table 5.

Incidence of Solicited Injection Site (Days 0; 3) and General Symptoms During the 43-Day Post-vaccination Period (Total Vaccinated Cohort)

Symptom MMR-RIT-1 (N = 283)
MMR-RIT-2 (N = 275)
MMR-RIT-3 (N = 283)
MMRII (N = 277)
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
Days 0; 3
Pain 70 24.8 (19.9; 30.3) 70 25.5 (20.5; 31.1) 79 28.0 (22.9; 33.6) 67 24.5 (19.5; 30.0)
Redness 45 16.0 (11.9; 20.8) 47 17.2 (12.9; 22.1) 41 14.5 (10.6; 19.2) 47 17.2 (12.9; 22.1)
Swelling 20 7.1 (4.4; 10.7) 26 9.5 (6.3; 13.6) 19 6.7 (4.1; 10.3) 15 5.5 (3.1; 8.9)
Days 0; 14
Irritability/fussiness 180 63.6 (57.7; 69.2) 141 51.3 (45.2; 57.3) 150 53.0 (47.0; 58.9) 153 55.2 (49.2; 61.2)
Drowsiness 133 47.0 (41.1; 53.0) 106 38.5 (32.8; 44.6) 113 39.9 (34.2; 45.9) 109 39.4 (33.6; 45.4)
Loss of appetite 111 39.2 (33.5; 45.2) 77 28.0 (22.8; 33.7) 110 38.9 (33.2; 44.8) 94 33.9 (28.4; 39.8)
Fever (rectal temp. ≥38.0°C) 65 23.0 (18.2; 28.3) 79 28.7 (23.5; 34.5) 64 22.6 (17.9; 27.9) 56 20.2 (15.6; 25.4)
Fever (rectal temp. >39.5°C) 10 3.5 (1.7; 6.4) 7 2.5 (1.0; 5.2) 9 3.2 (1.5; 6.0) 8 2.9 (1.3; 5.6)
Days 0; 42
Fever (rectal temp. ≥38.0°C) 103 36.4 (30.8; 42.3) 104 37.8 (32.1; 43.8) 104 36.7 (31.1; 42.7) 85 30.7 (25.3; 36.5)
Fever (rectal temp. >39.5°C) 20 7.1 (4.4; 10.7) 14 5.1 (2.8; 8.4) 18 6.4 (3.8; 9.9) 13 4.7 (2.5; 7.9)
Localized/generalized rash 72 25.4 (20.5; 30.9) 74 26.9 (21.8; 32.6) 60 21.2 (16.6; 26.4) 69 24.9 (19.9; 30.4)
Parotid gland swelling 3 1.1 (0.2; 3.1) 3 1.1 (0.2; 3.2) 5 1.8 (0.6; 4.1) 2 0.7 (0.1; 2.6)

Abbreviations: MMR, measles-mumps-rubella; N, number of subjects having received the documented dose; n/%, number/percentage of subjects reporting a specified symptom; 95% CI, exact 95% confidence interval.